Derek Bagley, Author at Endocrine News

Dosage Flexibility of Liquid Hypothyroidism Treatment Introduced for Patients and Clinicians

Americans diagnosed with hypothyroidism and their clinical providers now have access to greater dosage flexibility within levothyroxine therapy, with three new dosage strengths of levothyroxine sodium oral solution now available to treat hypothyroidism. IBSA Pharma markets the drug as Tirosint®-SOL. The unique new dosing options – 37.5, 44 and 62.5 micrograms – are a first...

Endocrine Society’s In-Training Exam Predicts Fellows’ Success on ABIM Board Exam

Endocrinology fellows and their program directors can use performance on the Endocrine Society’s in-training self-assessment tool to gauge how likely fellows are to pass the American Board of Internal Medicine-Endocrinology, Diabetes, and Metabolism Certification Examination (ABIM-ECE), according to a new study published in the Journal of the Endocrine Society. The study found clinical endocrinology fellows’...

Continuous Glucose Monitor Developed to Integrate Data Directly into Electronic Health Record

HealthPartners Institute’s International Diabetes Center (IDC) recently developed and piloted a process for incorporating patients’ continuous glucose monitoring (CGM) data directly into the electronic health record (EHR), improving clinician access to glucose information. During a presentation at the American Diabetes Association’s 81st Scientific Sessions, IDC medical director Amy Criego, MD, described this process for integrating...

Conquering Cancer: How a Newly Discovered Mutation Could Be a Game Changer in Treating Adrenal Carcinoma

The discovery of a new mutation could eventually hold the key to treating patients with adrenal carcinoma. Endocrine News talks with Emilia Pinto, PhD, a St. Jude’s Children’s Research Hospital scientist, who hopes that this new finding will raise awareness around the world in families who might be at a greater risk for this rare...

Tildacerfont Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia

Patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) may benefit from the drug tildacerfont, according to the results from two Phase 2 clinical studies recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Chris N. Barnes, PhD, of Spruce Biosciences (who funded the trial), point out that...

FDA Clears iOS App to Simplify Diabetes Management

The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...

Devil in the Details: The Impact of the First Interchangeable Biosimilar Insulin

[Editor’s Note: This post has been updated to include comments from Rita Kalyani, MD.] When the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product last month, many were hailing this as a breakthrough in treating diabetes. The impacts could be immediately felt by people rationing their insulin due to cost as...

Editor’s Page: No Place Like Work Home

Seventeen voicemails, 14 boxes of Endocrine News, and a Costa Coffee tumbler bought in London in 2019 that was in dire need of a good scrubbing. That’s what awaited me when I returned to my office at the Endocrine Society headquarters in Washington D.C. for the first since March 13, 2020. Honestly, it was good...